We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
Read MoreHide Full Article
Key Takeaways
CLOV delivered 53% YoY growth in Medicare Advantage PPO membership during the 2026 AEP.
CLOV retained over 95% of members by keeping plan benefits stable and expanding presence across core markets.
CLOV expects GAAP net income profitability in 2026, supported by retention, CA use and SG&A efficiency.
Clover Health Investments(CLOV - Free Report) has reported strong results from the 2026 Annual Enrollment Period (AEP), delivering 53% year-over-year growth in Medicare Advantage PPO membership. After a strong enrollment period, the company is starting 2026 with total membership increasing to 153,000, reflecting growth in core markets where Clover Health has broad Clover Assistant (CA) coverage and an integrated Home Care model. As a result, Clover Health believes it will achieve full-year GAAP net income profitability in 2026.
Per management, the company is starting 2026 in a strong financial position to show the robustness of Clover Health’s model, with strong growth in new members, high retention of existing members, improving performance across member groups and continued benefits from the Clover Assistant. This disciplined growth approach, coupled with strong retention, positions the company to achieve GAAP net income profitability for the first time in 2026.
CLOV Stock’s Trend Following the News
Following the announcement, shares of Clover Health rallied 10.6% at yesterday’s closing. Over the past six months, the stock has lost 7% compared with the industry’s 16.6% decline, However, the S&P 500 has risen 13.7% during the same time frame.
In the long run, achieving full-year GAAP net income profitability would mark an important inflection point for Clover Health Investments. Membership growth and retention, improved cohort performance, operating leverage from SG&A efficiency and the scaling impact of Clover Assistant could drive margins and earnings. These dynamics position Clover Health to demonstrate the scalability of its technology-enabled MA model while laying the foundation for sustainable growth beyond.
CLOV currently has a market capitalization of $1.45 billion.
Image Source: Zacks Investment Research
More on the AEP Performance & Profitability Outlook
Clover Health expects multiple tailwinds to support profitability, including improvement in the performance of new members and continued strong results from returning members, alongside sustained membership growth. This outlook is supported by higher payments from its 4.0-star-rated PPO plans in 2026, a favorable CMS rate update and increased Part D subsidies, strong member retention, expanded use of the Clover Assistant by PCP and improved operating efficiency as SG&A costs decline with scale.
By maintaining stable plan benefits year over year, Clover Health retained more than 95% of its members during the enrollment period and built a stronger presence in local communities. This shows the durability of the company’s membership base and its plans to continue to offer strong value to members. CLOV saw intentional growth in its PPO plans, with new members switching from other Medicare Advantage plans within Clover’s core markets.
Clover Health’s 2026 AEP results underscore the effectiveness of its focused growth strategy. More than 97% of its Medicare Advantage members are enrolled in its main PPO plan. For the second consecutive year, this plan is ranked the number one PPO plan in the country based on HEDIS quality measures. Clover Health’s AI-enabled, industry-leading quality highlights the strong quality of care it provides and the solid financial performance of its model.
Industry Prospects Favoring Market
Going by data provided by Precedence Research, the individual health insurance market is valued at $150.05 billion in 2025 and is expected to witness a CAGR of 6.43% through 2035. Factors like the changing landscape of healthcare and the need for protection against medical expenses, the integration of technology to enhance customer experiences through digital platforms, telehealth services and data-driven insights improving service efficiency and customer satisfaction influence market growth.
Other News
Counterpart Health, a subsidiary of Clover Health, reported strong 2025 results, showing how its AI-powered Counterpart Assistant (CA) improves care quality and lowers costs. Adoption of the platform grew rapidly, with live third-party clinicians increasing by more than 450% year over year across multiple states.
Data showed that returning Clover members whose primary care physicians (PCPs) use CA achieved about a 1,500 basis point improvement in medical cost ratios compared to those without CA. Counterpart’s technology also supported the nation’s top-ranked PPO Medicare Advantage HEDIS quality scores for the second consecutive year.
Clinical studies released in 2025 showed earlier diagnosis of chronic diseases like COPD, fewer hospitalizations and readmissions for conditions such as heart failure and COPD and better outcomes in underserved communities. In addition, Counterpart expanded its platform with ambient scribing, natural-language search, proactive visit summaries and enterprise-level tools, positioning it as a full clinical operating system for value-based care.
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the Zacks Consensus Estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Phibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
Omnicell, carrying a Zacks Rank #2 at present, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 41.7%. Revenues of $311 million beat the Zacks Consensus Estimate by 5.6%.
OMCL has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 27.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 38.65%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
Key Takeaways
Clover Health Investments(CLOV - Free Report) has reported strong results from the 2026 Annual Enrollment Period (AEP), delivering 53% year-over-year growth in Medicare Advantage PPO membership. After a strong enrollment period, the company is starting 2026 with total membership increasing to 153,000, reflecting growth in core markets where Clover Health has broad Clover Assistant (CA) coverage and an integrated Home Care model. As a result, Clover Health believes it will achieve full-year GAAP net income profitability in 2026.
Per management, the company is starting 2026 in a strong financial position to show the robustness of Clover Health’s model, with strong growth in new members, high retention of existing members, improving performance across member groups and continued benefits from the Clover Assistant. This disciplined growth approach, coupled with strong retention, positions the company to achieve GAAP net income profitability for the first time in 2026.
CLOV Stock’s Trend Following the News
Following the announcement, shares of Clover Health rallied 10.6% at yesterday’s closing. Over the past six months, the stock has lost 7% compared with the industry’s 16.6% decline, However, the S&P 500 has risen 13.7% during the same time frame.
In the long run, achieving full-year GAAP net income profitability would mark an important inflection point for Clover Health Investments. Membership growth and retention, improved cohort performance, operating leverage from SG&A efficiency and the scaling impact of Clover Assistant could drive margins and earnings. These dynamics position Clover Health to demonstrate the scalability of its technology-enabled MA model while laying the foundation for sustainable growth beyond.
CLOV currently has a market capitalization of $1.45 billion.
Image Source: Zacks Investment Research
More on the AEP Performance & Profitability Outlook
Clover Health expects multiple tailwinds to support profitability, including improvement in the performance of new members and continued strong results from returning members, alongside sustained membership growth. This outlook is supported by higher payments from its 4.0-star-rated PPO plans in 2026, a favorable CMS rate update and increased Part D subsidies, strong member retention, expanded use of the Clover Assistant by PCP and improved operating efficiency as SG&A costs decline with scale.
By maintaining stable plan benefits year over year, Clover Health retained more than 95% of its members during the enrollment period and built a stronger presence in local communities. This shows the durability of the company’s membership base and its plans to continue to offer strong value to members. CLOV saw intentional growth in its PPO plans, with new members switching from other Medicare Advantage plans within Clover’s core markets.
Clover Health’s 2026 AEP results underscore the effectiveness of its focused growth strategy. More than 97% of its Medicare Advantage members are enrolled in its main PPO plan. For the second consecutive year, this plan is ranked the number one PPO plan in the country based on HEDIS quality measures. Clover Health’s AI-enabled, industry-leading quality highlights the strong quality of care it provides and the solid financial performance of its model.
Industry Prospects Favoring Market
Going by data provided by Precedence Research, the individual health insurance market is valued at $150.05 billion in 2025 and is expected to witness a CAGR of 6.43% through 2035. Factors like the changing landscape of healthcare and the need for protection against medical expenses, the integration of technology to enhance customer experiences through digital platforms, telehealth services and data-driven insights improving service efficiency and customer satisfaction influence market growth.
Other News
Counterpart Health, a subsidiary of Clover Health, reported strong 2025 results, showing how its AI-powered Counterpart Assistant (CA) improves care quality and lowers costs. Adoption of the platform grew rapidly, with live third-party clinicians increasing by more than 450% year over year across multiple states.
Data showed that returning Clover members whose primary care physicians (PCPs) use CA achieved about a 1,500 basis point improvement in medical cost ratios compared to those without CA. Counterpart’s technology also supported the nation’s top-ranked PPO Medicare Advantage HEDIS quality scores for the second consecutive year.
Clinical studies released in 2025 showed earlier diagnosis of chronic diseases like COPD, fewer hospitalizations and readmissions for conditions such as heart failure and COPD and better outcomes in underserved communities. In addition, Counterpart expanded its platform with ambient scribing, natural-language search, proactive visit summaries and enterprise-level tools, positioning it as a full clinical operating system for value-based care.
Clover Health Investments, Corp. Price
Clover Health Investments, Corp. price | Clover Health Investments, Corp. Quote
CLOV’s Zacks Rank & Stocks to Consider
Currently, CLOV carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AtriCure (ATRC - Free Report) , Phibro Animal Health (PAHC - Free Report) and Omnicell (OMCL - Free Report) .
AtriCure, currently flaunting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 adjusted loss per share of 1 cent, 90.9% narrower than the Zacks Consensus Estimate. Revenues of $134.3 million beat the Zacks Consensus Estimate by 2.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ATRC has an estimated earnings growth rate of 64.2% for 2025 compared with the industry’s 12.2% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 67.06%.
Phibro Animal Health, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2025 adjusted earnings per share (EPS) of 73 cents, which surpassed the Zacks Consensus Estimate by 23.7%. Revenues of $363.9 million beat the Zacks Consensus Estimate by 2.6%.
PAHC has an estimated long-term earnings growth rate of 12.8% compared with the industry’s 13.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 20.77%.
Omnicell, carrying a Zacks Rank #2 at present, reported third-quarter 2025 adjusted EPS of 51 cents, which surpassed the Zacks Consensus Estimate by 41.7%. Revenues of $311 million beat the Zacks Consensus Estimate by 5.6%.
OMCL has an estimated long-term earnings growth rate of 9.4% compared with the industry’s 27.9% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 38.65%.